https://www.evitria.com/journal/antibodies/history-antibodies/2026-05-07T13:09:56+00:00https://www.evitria.com/journal/cho-cells/cho-cells/2026-05-07T15:06:39+00:00https://www.evitria.com/journal/afucosylated-antibodies/afucosylated-antibody-introduction/2026-04-28T08:42:49+00:00https://www.evitria.com/journal/cho-cells/mammalian-cell-culture/2026-04-28T09:34:10+00:00https://www.evitria.com/journal/recombinant-antibodies/recombinant-protein/2026-06-16T13:31:42+00:00https://www.evitria.com/journal/antibodies/cro-antibody-production/2026-05-07T13:59:14+00:00https://www.evitria.com/journal/afucosylated-antibodies/antibody-dependent-cellular-cytotoxicity/2026-04-30T08:49:20+00:00https://www.evitria.com/journal/antibodies/polyclonal-monoclonal-recombinant-antibodies-comparison/2026-06-16T13:33:33+00:00https://www.evitria.com/journal/cho-cells/how-to-grow-mammalian-cell-culture/2026-04-22T11:58:14+00:00https://www.evitria.com/journal/recombinant-antibodies/recombinant-antibody/2026-05-11T08:47:07+00:00https://www.evitria.com/journal/afucosylated-antibodies/glycoengineered-antibodies/2026-06-16T13:52:38+00:00https://www.evitria.com/journal/cho-cells/hek293-cells-vs-cho-cells/2026-04-30T08:51:13+00:00https://www.evitria.com/journal/antibodies/fc-silenced-antibody-therapeutic-antibodies-reduced-side-effect-profile/2026-06-16T13:33:49+00:00https://www.evitria.com/journal/recombinant-antibodies/true-fc-silencing-technology-str-mabsolve/2026-04-23T06:00:05+00:00https://www.evitria.com/journal/monoclonal-antibodies/monoclonal-antibodies/2026-06-16T11:28:01+00:00https://www.evitria.com/journal/news/evitria-ag-announces-license-of-mabsolve-str-technology/2026-06-16T13:53:12+00:00https://www.evitria.com/journal/antibodies/in-vivo-in-vitro-antibody-production/2026-06-16T13:32:05+00:00https://www.evitria.com/journal/antibodies/antibodies-medicine-research/2026-06-16T13:33:45+00:00https://www.evitria.com/journal/news/genovis-service-agreement-fast-lc-ms-analysis/2026-06-16T13:53:14+00:00https://www.evitria.com/journal/cho-cells/chinese-hamster/2026-06-16T13:33:35+00:00https://www.evitria.com/journal/recombinant-antibodies/his-tagged-proteins-purification/2026-04-29T10:39:18+00:00https://www.evitria.com/journal/cho-cells/cell-culture/2026-06-16T13:33:41+00:00https://www.evitria.com/journal/cho-cells/application-cell-culture/2026-04-30T08:51:10+00:00https://www.evitria.com/journal/monoclonal-antibodies/what-is-monoclonal-antibody/2026-04-28T08:44:09+00:00https://www.evitria.com/journal/recombinant-antibodies/application-recombinant-proteins/2026-04-30T08:50:31+00:00https://www.evitria.com/journal/cho-cells/mammalian/2026-06-16T13:33:34+00:00https://www.evitria.com/journal/recombinant-antibodies/what-is-recombinant/2026-04-28T08:44:01+00:00https://www.evitria.com/journal/monoclonal-antibodies/therapeutic-monoclonal-antibodies/2026-06-16T13:33:44+00:00https://www.evitria.com/journal/monoclonal-antibodies/advantages-monoclonal-antibodies/2026-05-07T13:16:26+00:00https://www.evitria.com/journal/monoclonal-antibodies/disadvantages-monoclonal-antibodies/2026-06-16T13:33:43+00:00https://www.evitria.com/journal/monoclonal-antibodies/application-monoclonal-antibodies/2026-06-16T13:31:53+00:00https://www.evitria.com/journal/recombinant-antibodies/recombinant-dna-technology/2026-07-15T06:52:16+00:00https://www.evitria.com/journal/recombinant-antibodies/advantages-disadvantages-recombinant-dna/2026-07-15T08:48:51+00:00https://www.evitria.com/journal/monoclonal-antibodies/who-produces-monoclonal-antibodies/2026-06-16T13:33:48+00:00https://www.evitria.com/journal/monoclonal-antibodies/monoclonal-antibody-production/2026-07-15T13:40:35+00:00https://www.evitria.com/journal/antibodies/differences-monoclonal-antibodies-recombinant-monoclonal-antibodies/2026-05-07T13:09:53+00:00https://www.evitria.com/journal/monoclonal-antibodies/monoclonal-antibody-drugs/2026-06-16T13:32:26+00:00https://www.evitria.com/journal/monoclonal-antibodies/types-monoclonal-antibodies/2026-07-15T10:41:29+00:00https://www.evitria.com/journal/news/major-milestone-evitria/2026-06-16T13:53:17+00:00https://www.evitria.com/journal/news/schweizer-expertise-weltweit-gefragt/2026-06-16T13:52:52+00:00https://www.evitria.com/journal/antibodies/antibody-production-cho-cells-advantages/2026-06-15T13:07:00+00:00https://www.evitria.com/journal/cho-cells/transient-transfection/2026-06-16T13:31:59+00:00https://www.evitria.com/journal/antibodies/what-are-polyclonal-antibodies/2026-06-16T13:33:37+00:00https://www.evitria.com/journal/antibodies/antibody-production/2026-06-16T13:33:32+00:00https://www.evitria.com/journal/recombinant-antibodies/recombinant-antibody-production/2026-06-11T09:23:34+00:00https://www.evitria.com/journal/monoclonal-antibodies/monoclonal-polyclonal-recombinant-antibodies/2026-06-16T13:37:53+00:00https://www.evitria.com/journal/what-is-a-cro/2026-06-16T13:31:48+00:00https://www.evitria.com/journal/recombinant-antibodies/recombinant-protein-expression-mammalian-cells/2026-04-30T08:50:50+00:00https://www.evitria.com/journal/recombinant-antibodies/what-is-recombinant-dna-used-for/2026-04-30T08:51:05+00:00https://www.evitria.com/journal/cdmo-antibody-production/2026-05-07T13:16:13+00:00https://www.evitria.com/journal/antibodies/cro-monoclonal-antibody-production/2026-05-07T13:49:39+00:00https://www.evitria.com/journal/antibodies/polyclonal-antibody-production/2026-04-28T07:43:47+00:00https://www.evitria.com/journal/news/dr-stefan-schmidt-new-ceo-evitria/2026-06-16T13:52:40+00:00https://www.evitria.com/journal/recombinant-antibodies/the-shortcut-to-reliable-diagnostic-control-and-assay-antibodies/2026-06-16T13:53:23+00:00https://www.evitria.com/journal/antibodies/in-vitro-antibody-production/2026-05-07T13:59:19+00:00https://www.evitria.com/journal/antibodies/antibody-production-in-animals/2026-04-30T08:49:33+00:00https://www.evitria.com/journal/antibodies/antibody-production-in-bacteria/2026-05-07T13:09:38+00:00https://www.evitria.com/journal/antibodies/presentation-richard-park-pegs-boston/2026-06-16T13:53:19+00:00https://www.evitria.com/journal/recombinant-antibodies/recombinant-protein-production/2026-05-07T13:16:55+00:00https://www.evitria.com/journal/cho-cells/hek-cells/2026-06-16T13:31:36+00:00https://www.evitria.com/journal/antibodies/in-vivo-antibodies/2026-04-30T08:49:57+00:00https://www.evitria.com/journal/recombinant-antibodies/recombinant-antibody-expression/2026-06-16T13:00:30+00:00https://www.evitria.com/journal/recombinant-antibodies/recombinant-antibody-purification/2026-06-16T13:32:14+00:00https://www.evitria.com/journal/antibodies/antibody-purification/2026-06-16T13:31:51+00:00https://www.evitria.com/journal/antibodies/antibody-production-by-b-cells/2026-04-30T08:49:30+00:00https://www.evitria.com/journal/antibodies/antibody-engineering/2026-06-16T13:32:21+00:00https://www.evitria.com/journal/antibodies/antibody-characterization/2026-06-16T13:32:23+00:00https://www.evitria.com/journal/afucosylated-antibodies/afucosylation-simply-explained/2026-06-16T13:33:46+00:00https://www.evitria.com/journal/afucosylated-antibodies/glycosylation-proteins/2026-06-16T13:32:07+00:00https://www.evitria.com/journal/antibodies/what-is-antibody/2026-06-16T13:31:40+00:00https://www.evitria.com/journal/antibodies/igg-antibodies/2026-07-14T07:30:08+00:00https://www.evitria.com/journal/antibodies/antibody-applications/2026-06-16T13:33:42+00:00https://www.evitria.com/journal/antibodies/antibody-discovery/2026-05-07T15:11:01+00:00https://www.evitria.com/journal/afucosylated-antibodies/how-are-afucosylated-antibodies-developed/2026-06-16T13:52:36+00:00https://www.evitria.com/journal/afucosylated-antibodies/applications-afucosylated-antibodies/2026-04-28T08:43:08+00:00https://www.evitria.com/journal/antibodies/benefits-transient-transfection/2026-04-23T07:26:00+00:00https://www.evitria.com/journal/antibodies/transient-transfection-vs-stable-transfection/2026-05-07T15:09:10+00:00https://www.evitria.com/journal/afucosylated-antibodies/therapeutic-antibodies/2026-06-16T13:52:30+00:00https://www.evitria.com/journal/news/evitria-and-lonza-sign-license-agreement/2026-06-16T13:52:54+00:00https://www.evitria.com/journal/cho-cells/reasons-cho-cells-protein-production/2026-04-23T05:58:57+00:00https://www.evitria.com/journal/news/engineering-bispecific-antibodies/2026-06-16T13:53:06+00:00https://www.evitria.com/journal/cho-cells/hek293-cells-recombinant-antibody-production/2026-06-16T13:33:36+00:00https://www.evitria.com/journal/bispecific-antibodies/difference-monoclonal-bispecific-antibody/2026-07-13T13:31:43+00:00https://www.evitria.com/journal/bispecific-antibodies/what-are-examples-of-bispecific-drugs/2026-07-13T12:56:47+00:00https://www.evitria.com/journal/bispecific-antibodies/formats-bispecific-antibodies/2026-07-09T12:28:58+00:00https://www.evitria.com/journal/bispecific-antibodies/companies-developing-bsabs/2026-07-09T13:30:14+00:00https://www.evitria.com/journal/bispecific-antibodies/fda-approved-bispecific-antibodies/2026-07-08T13:15:43+00:00https://www.evitria.com/journal/bispecific-antibodies/side-effects-bsabs/2026-07-09T11:55:09+00:00https://www.evitria.com/journal/bispecific-antibodies/bispecific-antibodies/2026-07-08T12:45:15+00:00https://www.evitria.com/journal/news/evitria-celebrates-15-years/2026-06-16T13:53:03+00:00https://www.evitria.com/journal/news/bengt-thorsson-and-johan-rockberg-to-join-atlas-antibodies-board-of-directors/2026-06-16T13:53:15+00:00https://www.evitria.com/journal/therapy-development/why-promising-antibody-candidates-fail-clinical-trials/2026-04-23T10:37:22+00:00https://www.evitria.com/journal/therapy-development/speed-vs-quality-in-early-drug-development/2026-04-23T05:58:43+00:00https://www.evitria.com/journal/therapy-development/bispecific-antibody-development-what-can-go-wrong/2026-06-16T13:52:34+00:00https://www.evitria.com/journal/therapy-development/risks-of-over-promising-early-stage-biologics-development/2026-06-16T13:53:01+00:00https://www.evitria.com/journal/therapy-development/stability-problem-why-some-recombinant-antibodies-dont-make-to-market/2026-06-16T13:52:42+00:00https://www.evitria.com/journal/high-throughput/early-antibody-developability-assessment-cho/2026-07-06T11:53:15+00:00https://www.evitria.com/journal/high-throughput/validating-ai-designed-antibodies/2026-07-06T09:08:10+00:00https://www.evitria.com/journal/high-throughput/hek293-vs-cho/2026-07-06T09:43:27+00:00https://www.evitria.com/journal/high-throughput/transient-vs-stable-expression-switch-htp/2026-06-15T12:09:53+00:00https://www.evitria.com/journal/high-throughput/transient-stable-expression-switch-htp/2026-07-06T11:50:15+00:00https://www.evitria.com/journal/high-throughput/htp-antibody-production/2026-07-06T09:15:05+00:00https://www.evitria.com/journal/high-throughput/batch-to-batch-variation-automation-htp/2026-07-06T08:29:51+00:00https://www.evitria.com/journal/news/aax-biotech-evitria-partnership-press-release/2026-05-07T13:59:22+00:00https://www.evitria.com/journal/high-throughput/htp-vs-preclinical-scale-antibody-production/2026-07-06T11:40:33+00:00https://www.evitria.com/journal/high-throughput/garbage-in-garbage-out-ai-antibody-discovery/2026-06-16T14:11:01+00:00https://www.evitria.com/journal/high-throughput/htp-screening-campaign-lead-comparability/2026-07-06T08:47:56+00:00https://www.evitria.com/journal/high-throughput/benefits-htp-antibody-expression/2026-07-06T09:55:50+00:00https://www.evitria.com/journal/high-throughput/primary-vs-secondary-screening-cho/2026-07-06T11:34:02+00:00https://www.evitria.com/journal/high-throughput/developability-by-design-5-readouts/2026-07-02T10:27:58+00:00https://www.evitria.com/journal/high-throughput/batch-effects-htp-antibody-production/2026-07-06T08:34:44+00:00https://www.evitria.com/journal/high-throughput/why-htp-screening-fails-manufacturing/2026-07-06T10:09:30+00:00https://www.evitria.com/journal/high-throughput/top-5-problems-htp-antibody-expression/2026-07-06T11:27:13+00:00https://www.evitria.com/journal/high-throughput/high-throughput-screening-hts-data/2026-07-02T10:09:06+00:00https://www.evitria.com/journal/high-throughput/hidden-costs-htp-hek293-material/2026-07-06T11:30:09+00:00https://www.evitria.com/journal/high-throughput/htp-antibody-production-turnaround-time/2026-07-06T10:00:57+00:00